Paper · 32147362
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA and 28 others. J Hepatol, 2020. Cited by 419 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. Papers, record 32147362. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32147362
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benzamides | Major topic |
| Imidazoles | Major topic |
| Liver | Major topic |
| Liver Cirrhosis | Major topic |
| Non-alcoholic Fatty Liver Disease | Major topic |
| Pyridines | Major topic |
| Biopsy | |
| Disease Progression | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Drug Monitoring | |
| Female | |
| Humans | |
| MAP Kinase Kinase Kinase 5 | |
| Male | |
| Middle Aged | |
| Protein Kinase Inhibitors | |
| Treatment Outcome |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03053050 | Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03053063 | Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Results | Yes | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 32,360,996 | STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. | https://conductscience.org/library/papers/32360996 |
Source PubMed
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by271
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 419 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,835,273 | siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42835273 | PubMed |
| 42,794,795 | From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794795 | PubMed |
| 42,761,919 | Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42761919 | PubMed |
| 42,719,321 | Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH). | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42719321 | PubMed |
| 42,687,024 | Current therapeutic landscape and future treatment perspectives of MASH. | Nature | 2026 | https://conductscience.org/library/papers/42687024 | PubMed |
| 42,650,797 | MASLD: Spatial Mechanisms and New Therapeutics. | Biomolecules | 2026 | https://conductscience.org/library/papers/42650797 | PubMed |
| 42,614,609 | The NLRP3 inflammasome in metabolic dysfunction-associated steatotic liver disease: role and advances in therapeutic targeting. | Front Immunol | 2026 | https://conductscience.org/library/papers/42614609 | PubMed |
| 42,608,656 | Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. | Aliment Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42608656 | PubMed |
| 42,606,110 | SR-A3 Promotes USP18-Mediated deISGylation of STING to Protect Against Myocardial Ischemia-Reperfusion Injury. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42606110 | PubMed |
| 42,599,594 | Hepatic stellate cells in alcoholic liver cirrhosis: mechanisms of fibrogenesis, plasticity, and fibrosis reversal. | Daru | 2026 | https://conductscience.org/library/papers/42599594 | PubMed |
1 to 10 of 271
See all 271 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MAP3K5 | 4,217 | PubTator's text mining | https://conductscience.org/library/genes/4217 | NCBI Gene |
| MAPK14 | 1,432 | PubTator's text mining | https://conductscience.org/library/genes/1432 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| SELONSERTIB | CHEMBL3916717 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL3916717 |
Source ChEMBL
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32147362
GET https://conductscience.org/api/papers/v1/32147362/authors?page=2